Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Cell Reports. Medicine|April 23, 2024
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemiaShady Adnan Awad, Olli Dufva, Jay Klievink, et al.Cancer Chemotherapy and Pharmacology|November 28, 2017
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trialIngrid Jakobsen Falk, Johan Lund, Henrik Gréen, et al.Bone Marrow Transplantation|October 22, 2020
Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter studyAhmed El-Serafi, Rui He, Wenyi Zheng, et al.Cell Death & Disease|September 26, 2021
Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cellsAlena Malyukova, Dorina Ujvari, Elham Yektaei-Karin, et al.Therapeutic Drug Monitoring|December 24, 2015
In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid LeukemiaKarin Skoglund, Johan Richter, Ulla Olsson-Strömberg, et al.Journal of Cancer Research and Clinical Oncology|March 25, 2017
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemiaHanna L M Rajala, Mohamed El Missiry, Anniina Ruusila, et al.Oncoimmunology|August 21, 2019
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-lineAnna Kreutzman, Bhagwan Yadav, Tim H Brummendorf, et al.European Journal of Haematology|August 2, 2014
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)Henrik Hjorth-Hansen, Leif Stenke, Stina Söderlund, et al.Blood Advances|April 3, 2025
Platelet activating histone/antihistone IgG complexes in anti-PF4 negative thrombosis and thrombocytopenia syndromeMax Esefeld, Stefan Handtke, Rainer Kaiser, et al.The New England Journal of Medicine|May 10, 2023
First-Line Venetoclax Combinations in Chronic Lymphocytic LeukemiaBarbara Eichhorst, Carsten U Niemann, Arnon P Kater, et al.Pageof 5